Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Merger or Acquisition (December 2024)
18 slides from Metropolis Healthcare's merger presentation, Dec 9, 2024
Slide 1: Cover letter to stock exchanges: Investor Presentation
Ref: MHL/Sec&Legal/2024-25/74 December 09, 2024 To, BSE Limited National Stock Exchange of India Ltd. Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are e
Slide 2: Metropolis Healthcare Limited & Core Diagnostics Acquisition Presentation
METROPOLIS HEALTHCARE LIMITED & Core Diagnostics Acquisition Presentation December 09, 2024
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company” or “MHL” or “Metropolis”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purc
Slide 4: Transaction Overview
Transaction Overview • Founded in 2012, Core is the leading Oncology (Cancer) testing lab player in India with 1,300+ test menu Core Diagnostics • Dominant player in super-specialty Oncology & Companion diagnostics Overview • Diversified Mix: B2C: 51% and B2B: 49% • Metropolis to Acquire 100% stake
Slide 5: About Core Diagnostics (1/2)
About Core Diagnostics (1/2) Key statistics Revenue1 (in INR Cr.) 150+ 22% 1 Reference lab 1,300+ High- & Onco 110 Revenue end Genomics 92 CAGR2 8 Satellite labs tests tests menu 62 59* 6 Sub- 1 Corporate FY22 FY23 FY24 H1FY25 200+ Cities Specialized & * Unaudited Covered Divisions 6 Other Offices •
Slide 6: About Core Diagnostics (2/2)
About Core Diagnostics (2/2) Core Diagnostics is India’s leading Oncology (cancer) specialty testing lab offering the most advanced testing in the industry. Revenue1 Sub-Speciality1 • 85%+ revenue contribution from Core Diagnostics is from 15% 16% Specialized testing 34 % 34% • One of the largest 24
Slide 7: Well positioned in the oncology testing market
Front End Focused Well positioned in the oncology testing market Peer 1 Peers’ Headquarters: Northern India Peer 1 Peer 2 Peer 5 Peer 2 Western India Peer 4 Peer 7 Peer 3 Southern India Peer 3 Peer 5 Peer 6 Peer 7 Back End Focused • Peers 1, 2, 3 & 4 are among the leading Peer 6 diagnostic players i
Slide 8: Opportunities in the Oncology Segment
Opportunities in the Oncology Segment Growth Drivers Indian Oncology Market+33% Size1 1. Rising Cancer Prevalence: ~1.4 million 3. Increased healthcare access: Onco new cancer cases annually. focused hospitals & New treatment guidelines 2. Advances in treatment technologies 4. Growing awareness abou
Slide 9: Entry Barriers in Oncology Testing Segment
Entry Barriers in Oncology Testing Segment Oncologists Centric Segment Rx Focused Diagnostics • Demands Personalized • No self prescribed tests Connect • Low volume and high-value tests • Dependent on the Oncologists • Testing only through prescriptions and trust and confidence on the hence oncologi
Slide 10: Role of Diagnostics in Cancer Treatment
Role of Diagnostics in Cancer Treatment The Cancer Patient Journey General Population Population at Risk Cancer Patients Survivorship Prevention Referral / Targeted Permanent Detection and Diagnosis Management Follow-ups Awareness Screening Therapy Survivorship Risk Treatment Remission Assessment Pl
Slide 11: Strategic Fit to Metropolis
Strategic Fit to Metropolis Strong presence in North & East 100+ Specialty Sales Team Together, the largest Oncology India with significant Revenue & 1,600+ Oncologists reach testing player in India Contributions Super specialized test menu in Quality asset with a high turnaround Oncology Testing po
Slide 12: Fit to Metropolis Strategic Pillars
Fit to Metropolis Strategic Pillars Metropolis’ Strategic Pillars Focus on B2C Rx focus through Specialty Doctors Connect Enhance Specialty Test Revenue Market Share Build Strong Doctors Connect in new geographies Increase Average Revenue per Patient 10
Slide 13: Investment Rationale (1/2)
Investment Rationale (1/2) Geographical Synergy Cost Synergies Will strengthen relationships Leveraging › Merging of overlapping labs › Procurement efficiency with the leading hospitals 1 Synergies & 4 › Manpower Optimization & and oncologists across North & East India Cross Selling Rationalization
Slide 14: Investment Rationale (2/2)
Investment Rationale (2/2) Strong Track- 1 Record 2 Governance 3 Synergy • Enhance MHL’s testing • The 1 st leading oncology • Fits into MHL’s DNA of capabilities in North India testing lab in the country Integrity, Empathy & • EPS Accretive from FY26. • Revenue CAGR of ~22% Accuracy • RoCE & RoE Ac
Slide 15: Core + MHL: Enhanced capabilities & new geography
Core + MHL : Enhanced capabilities & new geography INR (Cr.) Metropolis Core Combined Oncology Revenue – by Test Type Total Revenue* 1,189 110 1,299 Specialty Revenue 440 93 533 MHL 60% 40% Specialty as a % Contribution 37% 85% 41% Core 30% 70% Oncology Reach Metropolis Core Combined Oncology Sales
Slide 16: Integration Plan
Integration Plan Phase-wise Integration Plan Closing date to 6 months 6 - 18 Months o Steering committee formation and integration roll-out o Redesign Organogram with retention plan for key team o Create a unified brand identity and align marketing o Synergy on COGS & Resource Optimization strategie
Slide 17: Management Commentary
Management Commentary . Ms. Ameera Shah, Mr. Surendran Chemmenkotil, Mr. Avadhut Joshi, Chairperson & Whole-time Chief Executive Officer Chief Business Development Director Officer “We recognize the significant potential of the “With the majority of Core’s revenue coming “This move aligns perfectly
Slide 18: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : http://www.sgapl.net/images/sgapl_logo.jpg Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Kamlesh Kulkarni Mr. Shogun Jain / Mr. Sagar Shroff E
Metropolis Healthcare — Merger or Acquisition (December 2024) on 6ix